COMPASS Pathways plc
corporate_fare Company Profile
COMPASS Pathways plc (NASDAQ:CMPS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for CMPS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 14 rated 8 or above. Recent SEC coverage for CMPS spans 10-Q, 8-K, 10-K, 424B5.
Recent high-impact activity:
- Compass Completes FDA NDA Submission for Psilocybin Depression Therapy
- Compass Pathways Q3 Loss Narrows to $9.8M as Cash Builds to $444M
- Compass Narrows Q3 Loss to $9.8M, Final NDA Filing Due Within Two Weeks
- COMP360 Phase 3 Shows ~4-Point MADRS Gain; Rollout Targets 8,500 SPRAVATO Sites
- COMP360 Shows Durable 52-Week Efficacy in Phase 3 COMP005; Stock Jumps 11%
Financial Snapshot
Short Interest & Short Volume
7.73 days to coverFINRA reported short interest of 17,201,909 shares in CMPS as of the October 30, 2026 settlement, a 2.6% decrease from the prior period — about 7.7 days to cover at its recent average daily volume. On November 20, 2026, 52.4% of CMPS volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.